These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35983925)

  • 21. Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.
    Billowria K; Das Gupta G; Chawla PA
    Anticancer Agents Med Chem; 2023; 23(2):124-141. PubMed ID: 35616682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
    Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
    Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-small cell lung cancer with
    Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
    Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
    Basse C; Chabanol H; Bonte PE; Fromantin I; Girard N
    Lung Cancer; 2022 Nov; 173():116-123. PubMed ID: 36198244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
    Park S; Park S; Kim TM; Kim S; Koh J; Lim J; Yi K; Yi B; Ju YS; Kim M; Keam B; Kim JS; Jeon YK; Kim DW; Kim YT; Heo DS
    Eur J Cancer; 2024 Sep; 208():114206. PubMed ID: 38981315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy.
    De Giglio A; Di Federico A; Gariazzo E; Metro G
    Med; 2024 Jan; 5(1):1-3. PubMed ID: 38218173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
    Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
    Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
    Jatkoe T; Wang S; Odegaard JI; Velasco Roth AM; Osgood D; Martinez G; Lucas P; Curtin JC; Karkera J
    J Mol Diagn; 2022 Nov; 24(11):1181-1188. PubMed ID: 35963523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.
    Pacheco JM
    Cancer Discov; 2021 Jul; 11(7):1617-1619. PubMed ID: 34284994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
    David GM; Maria Del Pilar BC; Cristina MR
    J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
    Remon J; Hendriks LEL; Cardona AF; Besse B
    Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC.
    Passiglia F; Malapelle U; Normanno N; Pinto C
    Cancer Treat Rev; 2022 Sep; 109():102438. PubMed ID: 35882108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
    Schmalz L; Bloomer C; Zhang W; Petty W
    Lung Cancer; 2023 Dec; 186():107400. PubMed ID: 37856922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
    Brazel D; Kroening G; Nagasaka M
    BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR-Mutant NSCLC: Spotlight on Amivantamab.
    Cancer Discov; 2023 Dec; 13(12):OF9. PubMed ID: 37878779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
    Haddish-Berhane N; Su Y; Russu A; Thayu M; Knoblauch RE; Mehta J; Xie J; Gibbs E; Sun YN; Zhou H
    Clin Pharmacol Ther; 2024 Mar; 115(3):468-477. PubMed ID: 37776107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
    Al-Obeidi E; Kelly K; Gandara DR; Riess JW
    JCO Precis Oncol; 2024 Apr; 8():e2300677. PubMed ID: 38603654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
    Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Wang M; Yang JC; Mitchell PL; Fang J; Camidge DR; Nian W; Chiu CH; Zhou J; Zhao Y; Su WC; Yang TY; Zhu VW; Millward M; Fan Y; Huang WT; Cheng Y; Jiang L; Brungs D; Bazhenova L; Lee CK; Gao B; Xu Y; Hsu WH; Zheng L; Jänne PA
    Cancer Discov; 2022 Jul; 12(7):1676-1689. PubMed ID: 35404393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.